Scarica l'app Stockscreener
183.23
1.14%
2.06
Dopo l'orario di chiusura:
181.50
-1.73
-0.94%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$181.17
Aprire:
$181.96
Volume 24 ore:
1.23M
Relative Volume:
1.33
Capitalizzazione di mercato:
$20.49B
Reddito:
$10.52B
Utile/perdita netta:
$999.00M
Rapporto P/E:
21.91
EPS:
8.3628
Flusso di cassa netto:
$1.22B
1 W Prestazione:
-1.92%
1M Prestazione:
-2.00%
6M Prestazione:
+5.57%
1 anno Prestazione:
+16.62%
Intervallo 1D:
$179.53
$183.38
Intervallo di 1 settimana:
$179.53
$197.55
Portata 52W:
$148.70
$197.55
Quest Diagnostics Inc Stock (DGX) Company Profile
Nome
Quest Diagnostics Inc
Settore
Industria
Telefono
(973) 520-2700
Indirizzo
500 PLAZA DRIVE, SECAUCUS
Confronta DGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
183.23 | 20.54B | 10.52B | 999.00M | 1.22B | 8.3628 |
|
TMO
Thermo Fisher Scientific Inc
|
571.91 | 210.70B | 43.74B | 6.59B | 6.17B | 17.30 |
|
DHR
Danaher Corp
|
222.73 | 155.94B | 24.27B | 3.50B | 4.86B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
638.60 | 50.97B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
147.46 | 41.30B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
219.91 | 37.17B | 15.70B | 1.24B | 2.01B | 6.9036 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-01-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | Jefferies | Buy |
| 2024-10-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Ripresa | Evercore ISI | In-line |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2024-02-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-01-03 | Iniziato | Barclays | Equal Weight |
| 2023-12-12 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-06-29 | Iniziato | Piper Sandler | Neutral |
| 2023-05-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-23 | Iniziato | Evercore ISI | In-line |
| 2022-11-17 | Downgrade | Citigroup | Neutral → Sell |
| 2022-08-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-23 | Downgrade | UBS | Buy → Neutral |
| 2022-02-02 | Downgrade | Jefferies | Buy → Hold |
| 2022-01-28 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-03-12 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Aggiornamento | Argus | Hold → Buy |
| 2020-07-29 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-06-09 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-04-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2019-04-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-03-18 | Ripresa | Credit Suisse | Neutral |
| 2019-01-31 | Downgrade | Argus | Buy → Hold |
| 2019-01-17 | Iniziato | UBS | Neutral |
| 2019-01-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Quest Diagnostics Inc Borsa (DGX) Ultime notizie
Argus Lifts Price Target on Quest Diagnostics to $210 From $195 - MarketScreener
Quest Diagnostics Incorporated (DGX) Stock Forecasts - Yahoo Finance
How to escape a deep drawdown in Quest Diagnostics IncorporatedWeekly Trend Summary & Target Return Focused Picks - newser.com
Truist Financial Reaffirms Their Hold Rating on Quest Diagnostics (DGX) - The Globe and Mail
How supply chain issues affect Quest Diagnostics Incorporated stockMarket Weekly Review & Growth Focused Investment Plans - newser.com
How dovish Fed policy supports Quest Diagnostics Incorporated stockPortfolio Risk Summary & Accurate Buy Signal Alerts - newser.com
How currency fluctuations impact Quest Diagnostics Incorporated stockJuly 2025 Price Swings & Advanced Technical Analysis Signals - newser.com
What Fibonacci levels say about Quest Diagnostics Incorporated reboundWeekly Earnings Recap & Low Risk High Reward Ideas - newser.com
Can Quest Diagnostics Incorporated stock surprise with earnings upsideJuly 2025 Market Mood & Stepwise Swing Trade Plans - newser.com
Barclays Maintains Quest Diagnostics (DGX) Equal-Weight Recommendation - Nasdaq
Quest Diagnostics Incorporated (DGX): A Bull Case Theory - MSN
Quest Diagnostics: Strong Q3, Steady (Not Spectacular) Growth Ahead (NYSE:DGX) - Seeking Alpha
Quest Diagnostics Analysts Increase Their Forecasts After Q3 Earnings - Benzinga
Quest Diagnostics Sees Solid Demand Even As Margins Slip - Finimize
Quest Diagnostics Margins a Blip as Fundamentals Stay Strong, Morgan Stanley Says - MarketScreener
Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock - sharewise.com
Barclays Lifts Price Target on Quest Diagnostics to $195 From $190, Maintains Equalweight Rating - MarketScreener
Quest Diagnostics Reports Third Quarter 2025 Financial Results, Raises Guidance for Full Year 2025 - MarketScreener
Morgan Stanley Raises Price Target on Quest Diagnostics to $207 From $191, Keeps Overweight Rating - MarketScreener
Quest Diagnostics (DGX): 15.4% Earnings Growth Challenges Slower-Growth Narrative - Yahoo Finance
Quest Diagnostics: Q3 Earnings Snapshot - Stamford Advocate
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight - GuruFocus
Can Quest Diagnostics Incorporated (QDI) stock retain market dominance2025 Price Action Summary & Momentum Based Trading Ideas - newser.com
Will Quest Diagnostics Incorporated stock profit from fiscal stimulus2025 Dividend Review & Breakout Confirmation Trade Signals - newser.com
Jefferies Maintains Quest Diagnostics (DGX) Buy Recommendation - Nasdaq
Quest Diagnostics Inc (DGX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Published on: 2025-10-21 17:43:02 - newser.com
Leerink Partners Raises Price Target for Quest Diagnostics (DGX) to $210 | DGX Stock News - GuruFocus
Why Quest Diagnostics Incorporated stock is a strong buy call2025 Support & Resistance & Long-Term Growth Stock Strategies - newser.com
Quest Diagnostics Inc (DGX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Quest Diagnostics Inc (DGX) Q3 2025 Earnings Call Highlights: St - GuruFocus
Leerink Partners Adjusts PT on Quest Diagnostics to $210 From $203, Maintains Outperform Rating - MarketScreener
Quest Diagnostics Reports Q3 Earnings, Shares Slide - Benzinga
Quest Diagnostics Incorporated Revises Financial Guidance for the Full Year Ending December 31, 2025 - MarketScreener
Tranche Update on Quest Diagnostics Incorporated's Equity Buyback Plan announced on October 20, 2010. - MarketScreener
Fertility Test Market Report 2025-2033, with Profiles of Quest Diagnostics, Mayo Clinic Laboratories, Ovation Fertility, Illume Fertility, Proov, BioMerieux, Labcorp, CCRM Fertility, and Maven Clinic - GlobeNewswire Inc.
Quest Diagnostics shares rise as strong clinical demand drives earnings beat - Investing.com Australia
Quest Diagnostics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Quest Diagnostics (DGX) Surpasses Q3 Earnings and Revenue Estimates - sharewise.com
Quest Diagnostics Stock Up on Q3 Earnings & Revenue Beat, Margins Rise - TradingView
Quest Diagnostics Ups Forecasts As Diagnostic Test Demand Rises - Finimize
Quest Diagnostics Q3 2025 Earnings: Revenue Surpasses Estimates at $2.82 Billion, Adjusted EPS at $2.60 - GuruFocus
Quest Diagnostics Q3 Adjusted Earnings, Revenue Rise; Annual Outlook Upgraded -- Shares Up Pre-Bell - MarketScreener
Quest Diagnostics Delivers Strong Growth And Raises Guidance - Finimize
Quest Diagnostics raises annual profit and revenue forecasts on lab test demand - MarketScreener
Quest Diagnostics (DGX) Exceeds Q3 Projections with Strong Finan - GuruFocus
Quest (NYSE:DGX) Posts Better-Than-Expected Sales In Q3 - The Globe and Mail
(DGX) Quest Diagnostics Expects 2025 Net Revenue Range $10.96B$11.00B, vs. FactSet Est of $10.87B - MarketScreener
Quest Diagnostics Q3 revenue beats estimates on higher demand - MarketScreener
Quest Diagnostics Reports Third Quarter 2025 Financial Results - TradingView
Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 - PR Newswire
Quest Diagnostics Inc Azioni (DGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):